Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Traws Pharma, Inc. Director's Dealing 2024

Feb 9, 2024

35199_dirs_2024-02-09_efb88f6c-068f-4685-adae-06f22bed16f9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2024-02-07

Reporting Person: Fruchtman Steven M (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-07 Common Stock M 21320 Acquired 69620 Direct
2024-02-07 Common Stock F 9212 $0.67 Disposed 60408 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-07 Restricted Stock Units $ M 21320 Disposed Common Stock (21320) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On February 7, 2022 the reporting person was granted 63,960 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.